FindTrial
Sign In

Minimization (optimization) of maintenance immunosuppression in kidney transplant recipients based on both T and B cell epitope analysis

Minimization of maintenance immunosuppression in kidney transplant recipients based on both T and B cell epitope analysis - Minimization of maintenance immunosuppression in kidney transplant recipients based on epitope analysis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000061578
Enrollment
100
Registered
2026-05-15
Start date
2026-05-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney transplantation

Interventions

The study will enroll patients with a very low risk of an immune response leading to de novo DSA production and favorable T-cell and B-cell epitope compatibility (i.e., low eplet mismatch and low PIRC

Sponsors

Aichi Medical University
Lead Sponsor
Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital Japanese Red Cross Kumamoto Hospital
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1 to 10 years post-transplant Transplants performed in 2016 or later Stable transplant kidney function (no change in transplant kidney function over the past 6 months) Low B cell epitope mismatch (eplet MM (ver.3.1 antibody verified for DRB, DQB and DQA) is 4 or less) and low T cell epitope mismatch (PIRCHE-II score is 175 or less)

Exclusion criteria

Exclusion criteria: History of rejection episode Sibling HLA haplotype identity (case of complete HLA haplotype match between siblings) Donor specific HLA antibody (DSA)-positive transplantation de novo DSA production

Design outcomes

Primary

MeasureTime frame
De novo DSA production status (Annual evaluation: covered by health insurance)—

Secondary

MeasureTime frame
Kidney graft function (eGFR) Presence of rejection (confirmed by kidney biopsy) Onset of adverse events such as infections, hypertension, dyslipidemia, diabetes and malignancy Graft failure—

Countries

Japan

Contacts

Public ContactTakaaki Kobayashi

Aichi Medical University Renal Transplant Surgery

takaaki.kobayashi@aichi-med-u.ac.jp0561-62-3311

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026